Healthcare
Sonendo, Inc.(SONX)
Live Price
Offline$0.60
+0.00% today
1Y Change
-47.83%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- -27.7%
- EPS Growth
- +9.2%
- Dividend Yield
- 0.0%
Coverage: 253 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sonendo, Inc. (SONX) is a Healthcare stock with listed on OTC. The stock last traded around $0.60 and down 47.8% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -27.7%, EPS growth of +9.2%, a dividend yield of 0.0%. What stands out right now is revenue -27.7%, EPS +9.2%, free cash flow +47.2% with operating margin -92.6% and ROIC -120.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SONX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-27.7% vs +7.6% peer median
Operating Margin
Below sector median
-92.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -27.7% and EPS is at +9.2%, with operating margin around -92.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -19.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | -23.7% | -25.0% |
2026 Mar 30, 2026 | โ | +0.0% | -34.0% | -34.0% |
2025 Nov 10, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SONX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SONX Max Drawdown
-98.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SONX and SPY.
Company Overview
Sonendo, Inc.
Other OTC
Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is headquartered in Laguna Hills, California.
- Leadership
- Bjarne Bergheim
- IPO Date
- Oct 29, 2021
- Employees
- 129
- Street Address
- 26061 Merit Circle
- Mailing
- Laguna Hills, CA, 92653
- Region
- Laguna Hills, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 766 3636
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- 4.6
Growth
- Revenue
- -27.7%
- EPS
- +9.2%
- Free Cash Flow
- +47.2%
Profitability
- Gross Margin
- 37.4%
- Operating Margin
- -92.6%
- Net Margin
- -88.4%
- ROE
- -166.8%
- ROIC
- -120.6%
Balance Sheet
- Debt/Equity
- 3.65
- Current Ratio
- 1.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.